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Pharmacokinetics and protein binding of prednisolone in
patients with nephrotic syndrome and patients undergoing
hemodialysis
HARALD BERGREM
Medical Department B and the Department of Clinical Pharmacology, Rikshospitalet University Hospital, Oslo, Norway
Pharmacokinetics and protein binding of prednisolone in patients with
nephrotic syndrome and patients undergoing hemodialysis. Pharmacoki-
netics and protein binding of intravenously administered prednisolone
were studied in seven patients with nephrotic syndrome and normal
serum creatinine, seven patients with chronic renal failure undergoing
hemodialysis, and 12 healthy control subjects. Compared to the control
subjects, the patients with nephrotic syndrome had a 24% lower peak
prednisolone serum concentration (P < 0.05), a 31% smaller area under
the time-concentration curve of total prednisolone (P < 0.05), a 39%
greater volume of distribution at steady state (P < 0.01), and a 32%
higher total body clearance of total prednisolone (P < 0.05). The free
fraction of prednisolone was 14% greater in the nephrotic patients (P <
0.05), and the area under the time-concentration curve of free predniso-
lone was 13% smaller (NS). The patients undergoing hemodialysis had a
33% longer elimination half-time (P < 0.05), a 35% greater area under
the time-concentration curve of total prednisolone (P < 0.01), and a
35% lower total body clearance (P < 0.01). The fraction of free
prednisolone was 8% lower in the dialysis patients than in the controls
(NS), but the area under the time-concentration curve of free predniso-
lone was 29% greater (P < 0.01) than in the control subjects. The
biological effects are probably determined by the amount of free
prednisolone in the body. From a pharmacokinetic point of view, the
present results suggest that reduction of the prednisolone dose may be
unnecessary in patients with nephrotic syndrome if the renal function is
otherwise normal, and that dose reduction may be possible in patients
with chronic renal failure undergoing hemodialysis. However, the
clinical relevance of these results can only be evaluated by appropriate
clinical studies.
Pharmacocinetique et liaison protéique de Ia prednisolone chez des
malades atteints de syndrome néphrotique et des malades en hémodialyse.
La pharmacocinetique et Ia liaison protéique de Ia prednisolone admin-
istrée par voie intra-veineuse ont été étudiées chez sept malades atteints
de syndrome nephrotique et avec une créatinine serique normale, sept
malades atteints d'insuffisance rénale chronique en hemodialyse, et 12
sujets contrhles sains. Par rapport aux subjets contrOles, les malades
atteints de syndrome néphrotique avaient un pie de concentration
sérique de prednisolone plus faible de 24% (P < 0,05), une surface sous
Ia courbe temps-concentration de prednisolone totale plus faible de 31%
(P < 0,05), un volume de distribution a l'équilibre plus élevé de 39% (P
< 0,01), et une clearance corporelle totale de prednisolone totale de
32% plus élevée (P < 0,05). La fraction libre de prednisolone était de
14% pIus élevée chez les malades nephrotiques (P < 0,05), et l'aire sous
Ia courbe temps-concentration de prednisolone libre de 13% plus faible
(NS). Les malades en hémodialyse avaient un temps de demi-élimina-
tion plus long de 33% (P < 0,05), une surface sous Ia courbe temps-
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concentration de prednisolone totale plus grande de 35% (P < 0,01), et
une clearance corporelle totale de 35% plus faible (P < 0,01). La
fraction de prednisolone libre était plus basse de 8% chez les malades en
hémodialyse par rapport aux contrôles (NS), mais Ia surface sous Ia
courbe temps-concentration de prednisolone libre était 29% plus élevee
(P < 0,01) que chez les sujets contrôles. Les effets biologiques sont
probablement déterminés par Ia quantité de prednisolone libre dans Ic
corps. D'un point de vue pharmacocinetique, ces résultats suggerent
que Ia reduction de Ia dose de prednisolone pourrait ne pas être
nécessaire chez les malades avec un syndrome néphrotique si Ia
fonction rénale est par ailleurs normale, et que Ia reduction de dose
pourrait être possible chez les malades en insuffisance rénale chronique
en hemodialyse. Toutefois, Ia signification clinique de ces résultats ne
peut être Cvaluée que par des etudes cliniques appropriées.
An increased incidence of glucocorticoid side effects has
been reported in prednisone-treated patients with hypoalbumi-
nemia [1, 2]. This is believed to be caused by an increased
concentration of free, biologically active prednisolone due to
reduced serum protein binding [1, 3]. Therefore, a reduction of
the prednisone dose has been recommended in such patients [1,
3, 4].
However, Gugler et al [5] have shown that although the in
vitro protein binding is reduced for phenytoin and clofibrate,
the concentration of free drug tends to normalize at the steady
state in patients with nephrotic hypoalbuminemia, and that
dosage reduction therefore is unnecessary. Similar mechanisms
may be operative for prednisolone, but the disposition of
prednisolone in patients with nephrotic syndrome has not been
studied systematically. Further, most studies of the protein
binding of prednisolone in patients with hypoalbuminemia have
been performed on single serum samples, sometimes after the
addition of prednisolone in vitro. Also, some of the patients
reported had an underlying liver or kidney disease which may
alter prednisolone disposition and thus obscure the effects of
hypoalbuminemia alone on glucocorticoid side effects [61.
Many kidney transplant recipients need dialysis treatment
after the transplantation before recovery or definite failure of
transplant function. Heparin is given in large doses during
hemodialysis, and the resulting increase in free fatty acids may
reduce the drug-binding capacity of albumin by competitive
binding [71. This could theoretically lead to an increased loss of
free prednisolone through the dialyzer, an effect which could be
detrimental to transplant recovery.
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Table 1. Clmica! details
Serum cre- Serum Pred-
atinine albumin ASAT niso-
Patient Age Weight mo1es/liter giliter U/liter lone Other
no. Sex years kg Diagnosis (55 to 126) (34 to 43) (13 to 38) mg/day drugs
Nephrotic syndrome patients
13 M 43 79 MCGN 100 24 18 10 F
14 M 15 64 MCGN 74 17 19 20 F
15 M 18 71 CGN 104 27 19 10 F, 5, B
16 F 36 74 LED 82 29 18 15 F, B
17 F 24 68 MGN 95 27 24 10 F, S
18 M 26 69 LED 80 25 21 20 F
19 M 56 78 MGN 112 22 26 20 F, S
Dialysis patients
20 M 33 54 DM 737 25 14 — I
21 M 32 73 CGN 1290 36 94 — —
22 F 59 50 CGN 940 3! 19 — B, PR
23 M 30 64 CGN 1142 33 18 — F, B
24 M 53 59 AMY 940 31 19 10 —
25 M 50 80 CGN 1330 32 15 — —
26 M 42 73 AMY 1370 32 16 7.5 B
Normal controls
ito 12 F 5 39 72 — 102 36 17 — —
M = 7 (26 to 52) (62 to 88) (92 to 113) (34 to 40) (12 to 28)
Abbreviations: MCGN, minimal change glomerulonephritis; CGN, chronic glomerulonephritis; LED, lupus nephropathy; MGN, membrane
glomerulonephritis; DM, diabetic nephropathy; AMY, amyloidosis; F, furosemide; 5, spironolactone; B, beta blocker; PR, prazosin; I, insulin.
To ascertain whether dosage adjustment of prednisolone is
indicated in these two clinical situations, the pharmacokinetics
and protein binding of prednisolone were studied in nephrotic
syndrome patients with normal serum creatinine and liver
function tests, in regular hemodialysis patients during dialysis,
and in healthy control subjects.
Methods
Seven patients with nephrotic syndrome, seven regular he-
modialysis patients, and 12 healthy volunteers gave their in-
formed consent to participate in the study. Clinical details are
presented in Table 1.
One patient with nephrotic syndrome had moderate edema at
the time of investigation, but none of the other patients had
clinically detectable edema. The nephrotic patients and two of
the dialysis patients had used prednisolone regularly for 2 to 16
months (mean, 6.6 months). The last prednisolone dose was
taken 24 hr before the study.
All subjects received 20 mg prednisolone sodium succinate
(Precortalone, Organon, Holland) corresponding to 15 mg pred-
nisolone given intravenously during 1 mm. In the hemodialysis
patients, dialysis was started immediately after the injection.
Heparin 3000 IU was given as a bolus injection at the start,
followed by 1500 lU/hr by continuous infusion during dialysis.
Blood samples were drawn from the arterial tubing 15 mm after
the injection of prednisolone, and hourly for 6 hr throughout the
dialysis. All patients were dialyzed with a dialyzer (Cordis Dow
4000, Miami, Florida). Blood flow, dialysate flow, and trans-
membrane pressure were kept equal in all patients during the
treatment. The healthy control subjects and the patients with
nephrotic syndrome had an in-dwelling venous canula in the
arm opposite to that where the intravenous injection was given.
Normal saline (0.5 ml), containing 50 IU/ml of heparin, was
used to keep the canula patent between samples. Blood samples
were drawn without venous stasis atO, 0.08, 0.25, 0,5, 0.75, 1,
1.5, 2, 4, 8, and 12 hr in the control subjects, and at 0.08, 0.25,
0.5, 1, 1.5, 2, 4, 6 and 7 hr in the nephrotic patients. The blood
samples were centrifuged, and serum was stored at —20°C until
it was analyzed.
Prednisolone concentrations were measured by a specific
radioimmunoassay [8]. Serum (0.5 ml) was extracted twice with
ether (recovery 95%). The combined extracts were evaporated
to dryness under air at 40°C, and the residue was reconstituted
in 0.1 M phosphate buffer. A 0.5 ml sample, 0.1 ml anti-
prednisolone antibody (Guildhay Antisera, Guildford, England,
titer 1:2500) and 0.1 ml H3-prednisolone (approximately 8500
cpm, S.A. 40 Ci/mmole, The Radiochemical Centre, Amer-
sham, England) were incubated overnight at 4°C. Free and
bound prednisolone was separated by incubation with 0.1 ml of
freshly prepared dextran/charcoal suspension (Norit Grade A,
1%, and Dextran 40.000 0.1%) on ice for 5 mm, followed by
centrifugation at 4°C at x 5500g for 15 mm. The bound fraction
was decanted into counting vials, 10 ml of scintillation fluid
(Hydroluma, Lumac Systems, Basel, Switzerland) added, and
the samples were counted in a liquid scintillation counter
(Packard 3375, Packard Instruments, United Technology,
Downers Grove, Illinois). The standard curve was generated
from two separately weighed standards and consisted of six
points in the 80 to 15 ng/ml range.
Plasma standards containing 80, 50, and 15 ng predniso-
lone/mi were extracted and analyzed with each assay. The
mean within-batch coefficient of variation was 3.7% (N = 10).
The between-batch coefficients of variation were 6.1, 6.4, and
16% (mean = 9.5%) for standards containing 80, 50, and 15 ng
prednisolone/ml, respectively (N = 20). The cross reactivity of
the antibody was less than 4% for cortisol and less than 2% for
prednisolone sodium succinate.
The serum protein binding of prednisolone was measured in
all sera collected after the intravenous injection by equilibrium
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dialysis at 37°C using the Dianorm apparatus (Diachema AG,
ZUrich, Switzerland), cellulose membranes with molecular
weight cut-off of 10,000, and isotonic Krebs-Ringer phosphate
buffers [91. Serum pH was measured in one serum sample from
each subject using an Astrup pH meter before and after
equilibrium dialysis [serum pH before equilibrium dialysis: 8.12
0.1 (SD), and after: 7.43 0.1 after, N = 16]. Separate
experiments showed that the protein binding of prednisolone
did not vary measurably within a pH range of 7.2 and 7.6.
Prednisolone H3, checked for purity (98%) by thin layer
chromatography, was added to the buffer to give approximately
30,000 cpm/ml. One milliliter of serum was dialyzed against 1 ml
buffer for 3 hr (equilibrium was reached in less than 2.5 hr).
Serum and buffer (200 d) were added in duplicate to 4 ml
scintillation fluid and counted using an internal standard for
quench correction. The recovery of radioactivity from the
dialysis system was 100%.
Serum standards from pooled sera to which prednisolone 500
and 50 ng/ml had been added were included in each protein
binding assay. The fraction of free prednisolone at equilibrium
was 29.6% 0.47 for the 500 ng/ml standard, and 12.3% 0.37
for the 50 nglml samples, giving a within-assay coefficient of
variation of 1.58 and 3.02%, respectively. The between-assay
coefficients of variation were 3.33% (500 nglml) and 6.16% (50
nglml) (N = 10). Serum protein concentrations were measured
in one sample from each subject before and after equilibrium
dialysis using a biuret method (A-Gent Total Protein Test,
Abbott Laboratories, Hospital Products Division, North Chica-
go, Illinois). The change in serum protein concentration before
and after equilibrium dialysis was used to calculate the volume
change in the serum compartment. The fraction of protein-
bound prednisolone at equilibrium was calculated by
(Serum dpm Buffer dpm)
Serum dpm
The concentration of total (free + bound) prednisolone in the
serum compartment was corrected for dilution and loss of drug
to the buffer compartment by the Behm-Wagner equation [101.
A
fV + (1 — fb)(Vo + V)
where Ccorr = total concentration of drug in serum compart-
ment at equilibrium; A, = total amount of drug initially in the
system; fb = fraction of protein bound drug at equilibrium; V, =
volume of serum compartment at equilibrium; V, = volume of
buffer compartment at equilibrium.
Pharmacokinetics The peak prednisolone serum concentra-
tions (Cmax) and the time of Cmax (Tmax) were read directly from
the experimental data. The elimination half-time (t112) was
expressed by 0.6931/3 with /3 as the apparent first order disposi-
Lion rate constant which was calculated by linear least squares
regression analysis of the logarithms of the terminal four serum
concentrations (five in the dialysis patients). The area under the
time-concentration curve (AUC) was measured by the trape-
zoid rule, the AUC from time t to infinity by CIf3 with C as the
last measured serum concentration. The volume of distribution
at steady state (VD) was calculated by DosexAUMC where
AUMC is the area under the first moment of the time-concen-
tration curve [111. The total body clearance (Cli) of predniso-
Doselone was calculated by —-- [121.
Based on the calculated serum concentrations of predniso-
lone in the dialysis cell at equilibrium (Ccorr), the corresponding
concentration of free prednisolone was obtained by the percent-
age of free drug at equilibrium. The AUC for the postequilibri-
urn dialysis total prednisolone serum concentrations (AUCC0rr
tot) and the corresponding area of free prednisolone (AUCcorr
free) were calculated by the trapezoid rule extrapolated
to infinity; the /3 for the calculation of the AUCcorr free
was obtained from the terminal four free prednisolone
concentrations.
The fraction of free prednisolone (Ffree) was calculated by
x 100. Results are presented as means 1 SD.
Statistical analysis was performed using the Wilcoxon test, A P
value equal to or smaller than 0.05 was considered statistically
significant.
Results
There was an initial rise in prednisolone serum concentra-
tions after the intravenous injection; Tmax ranged from 0.08 to 1
hr. There was no statistical difference in Tmax between the
groups. Compared to the control subjects, the patients with
nephrotic syndrome had a lower Cmax (366 vs. 481 ng/ml, P <
0.05), a smaller AUC (1787 vs. 2578 ng/ml/hr, P < 0.05), a larger
VD. (43.5 vs. 26.7 liters, P < 0.01), and a higher Cl (151 vs.
102 ml/min, P <0.05). The Ffree was significantly greater in the
nephrotic patients than in the control subjects (15.2% vs.
13.1%, P < 0.05), but the AUCcorr free tended to be smaller in
the patients (234 vs. 270 ng/rnl, NS).
The dialysis patients had a longer t12 than the controls (4.74
vs. 3.17 hr, P < 0.05), a larger AUC (3982 vs. 2578 ng/ml/hr, P
<0.01), and a lower Cl (66 vs. 102 mI/mm, P < 0.01). There
was no significant difference between the dialysis patients and
the control subjects in Cmax (535 vs. 481 ng/ml), VD (26.5 vs.
26.7 liters), or prednisolone Ffiee (12.1% vs. 13.1%). The
AUCcorr free was significantly larger in the dialysis patients than
in the control subjects (381 vs. 270 nglml/hr, P <0.01). Results
are detailed in Table 2 and Figure 1. The relationship between
the percentage of free drug after equilibrium dialysis and the
corresponding total serum concentration (Ccorr) is shown in
Figures 2 and 3.
There was a significant (P < 0.01) negative linear correlation
(r =
—0.90) between the serum albumin concentration and the
VD in the patients with nephrotic syndrome (Fig. 4).
Discussion
Prednisolone succinate is a biologically inactive ester pro-
drug of prednisolone which did not react with the present
antiprednisolone antibody. The rise in prednisolone concentra-
tions found after an intravenous injection thus reflects the rate
of ester hydrolysis. The extent of hydrolysis was assumed to be
equal in the three groups studied.
The effect of hypoalbuminemia on the binding of drugs to
serum proteins has been the subject of a number of studies,
reviewed by Gugler and Azarnoff in 1977 [6]. For prednisolone,
hypoalbuminemia of various etiologies was associated with an
increased incidence and severity of major glucocorticoid side
effects, mainly ascribed to decreased protein binding of prednis-
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Table 2. Results
Patient no.
Cmax
ng/ml
Tmax
hours ty2hours
AUC
ng/ml/hr
VD
liters
Ci
mi/mm
Normal controls
1 518 0.27 2.87 2132 28.2 117
2 489 0.27 3.10 2377 27.7 105
3 441 0.50 3.66 2734 28.7 91
4 558 0.25 3.72 3251 24.2 77
5 452 0.25 2.52 2015 23.3 124
6 551 0.25 3.43 2598 27.9 96
7 384 0.25 2.83 1978 31.0 126
8 330 0.50 2.82 1868 30.2 134
9 540 0.25 3.64 3538 22.8 71
10 383 0.50 2.92 1935 32.3 129
11 509 0.85 2.68 2762 22.3 91
12 617 1.00 3.82 3743 22.3 67
Mean 481 0.43 3.17 2578 26.7 102
1 SD 81 0.25 0.44 621 3.6 23
Nephrotic syndrome
patients
13 374 0.50 2.10 1434 34.4 174
14 189 0.75 8.50 2201 73.0 114
15 488 0.25 4.19 2895 31.1 86
16 489 0.25 1.40 1270 25.1 197
17 433 0.25 4.03 1842 44.6 136
18 355 0.08 2.65 1479 34.4 169
19 233 0.50 4.02 1390 61.7 180
Mean 366 0.37 3.84 1787 43.5 151
1 SD 188 0.20 2.32 584 17.6 40
Dialysis patients
20 438 1.00 3.32 2665 28.5 94
21 498 0.25 4.66 3715 26.4 67
22 510 0.25 3.80 3044 28.4 82
23 550 0.25 4.29 3563 26.4 70
24 591 0.27 5.66 5059 24.4 49
25 566 0.25 5.75 4807 26.6 52
26 591 0.33 5.71 5018 24.9 50
Mean 535 0.37 4.74 3982 26.5 66
1 si 56 0.28 0.99 981 1.6 17
olone found in sera from such patients [1, 2]. However, other
factors such as decreased hepatic and/or renal function may
have affected the clearance and protein binding of prednisolone,
thus obscuring the effects of hypoalbuminemia alone.
In the present study, the nephrotic patients had normal serum
creatinine and liver function tests. As the quality of albumin as
a binding protein is not altered in nephrotic syndrome as it is in
uremia [13], the decreased protein binding of prednisolone in
the present study may be assumed to be mainly due to hypoal-
buminemia. Renal loss of cortisol binding globulin, which also
binds prednisolone and has a molecular weight close to that of
albumin, may have contributed to the decreased binding. Furo-
semide and spironolactone, used by all and three nephrotic
patients, respectively, are bound to serum albumin but not to
cortisol-binding globulin [14]. Because of its relatively short
elimination t112 (0.3 to 1.6 hr) and different chemical structure,
furosemide is unlikely to interfere with the protein binding of
prednisolone. Spironolactone and its metabolite, canrenone,
each have a t112 of 5 to 40 hr [15]. Spironolactone has a stronger
affinity for human serum albumin than prednisolone has [161. A
possible displacing effect of spironolactone on the protein
binding of prednisolone therefore cannot be excluded.
Gugler and Azarnoff showed that the free concentration of
phenytoin and clofibrate tended to normalize at steady state in
patients with nephrotic hypoalbuminemia due to a decrease in
t112 and an increase in VD and Cl [6]. In the present study, the
decreased Cmax and AUC and the increased VD and Cl show
that similar pharmacokinetic changes take place for predniso-
lone. Although the Ffree was higher in the patients, the amount
of free drug (AUCcorr free), calculated from the postequilibrium
dialysis concentrations, was the same, or even smaller, than in
the control subjects (Fig. 1). Pharmacological effects are be-
lieved to be determined by the free drug [1, 17]. From a
pharmacokinetic point of view, the dose-effect relationship
would therefore be expected to be similar in both patients and
control subjects. However, the dose-effect relationship might
also be affected by an altered serum protein: tissue binding ratio
secondary to hypoalbuminemia.
Prednisolone pharmacokinetics during hemodialysis have
been reported in a previous study of two patients. A t,2 of
approximately 3.5 to 4 hr could be calculated from the data
provided, and similar results were obtained when the same
patients were studied without dialysis [181.
Normally, 5 to 34% of a prednisolone dose is excreted
unchanged in the urine [19—23], and the renal clearance of
prednisolone is well correlated to the creatinine clearance [24].
The prolonged ti!2 and the reduced Cl in the present dialysis
patients are most likely caused by a combination of a very low
renal clearance of prednisolone and a decreased hepatic drug
clearance, which has been found in uremic patients [25]. Cross
reaction between retained prednisolone metabolites and the
antiprednisolone antibody could theoretically cause an appar-
Nephrotic syndrome
r = 0.90
p <0.01
= 33.26— 0.20X
880 Bergrem
.
4000 480 28
S
.
3800 440 24
S
a, 203400 • 400 0
3000 360' E 16S -D
• • a
E 2600 12• E 320 , 18 ILS • S SC c 17- 8
2200 280-' ' 16 •
* •
'°14-1800 240 •
.13-—.
S
1400 200 • : 12 - 100 200 300 400 500
• 11 • Corrected prednisolone serum concentration, ng/mI
1000 5 160 10 • Fig. 3. Posiequilibrium dialysis total prednisolone serum concentra-NC NS 0 NC NS D NC NS 0 tions and the corresponding percentage of free prednisolone in seven
AUcor tot AUCcorr free Ftree patients with chronic renal failure undergoing hemodialvsis (S—S)
and 12 normal control subjects (0—0).
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Prednisolone protein binding during hemodialysis did not
4 differfrom that seen in healthy control subjects (Fig. 3). Protein
________________________________________________
binding of another neutral steroid, digitoxin, is reduced signifi-
0 100 200 300 400 500 cantly during hemodialysis [261, due to the marked increase in
Corrected prednisolone serum concentration, ag/mi free fatty acids by heparin displacing digitoxin from its binding
Fig. 2. Posiequilibrium dialysis total prednisolone serum concentra- sites. Wagner et al [27] have shown that a small dose of heparin
tions and the corresponding percentage of free prednisolone in seven used to keep an indwelling venous canula patent did not alter
patients with nephrotic syndrome (•—•) and 12 normal control the protein binding of prednisolone, and Rocci and Jusko [281
subJects (0—0). did not find a change in prednisolone protein binding when
heparin was injected intravenously and when it was added
directly to the collected blood.
ent prolongation of' the prednisolone t112. Cross reaction is, The recommendation that patients with hypoalbuminemia
however, unlikely to be of significant importance, as conjugated should have reduced prednisolone doses is based on the high
and polar metabolites are not extracted by ether which was incidence of glucocorticoid side effects in patients with hypoal-
used for prednisolone extraction in the present radio- buminemia of various etiologies, and on the finding of a reduced
immunoassay. Further, the cross reactivity of the maior metab- protein binding of prednisolone in single sera from such pa-
olite, 20 dihydro-prednisolone, is less than 10% in the presence tients. The results of this study in nephrotic syndrome patients
of prednisolone [181. with normal serum creatinine and normal liver function tests
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suggest that the role of reduced renal and/or hepatic function
nay have been underestimated in the development of glucocor-
;icoid side effects in patients with hypoalbuminemia in earlier
;tudies. The serum protein binding of prednisolone is dynamic
tnd must be considered together with other pharmacokinetic
nformation, as exemplified by the similar AUCcorr free in
ephrotic syndrome patients and controls in the present study.
The present results suggest that adjustment of the predniso-
one dose may not be necessary in nephrotic syndrome patients
with normal serum creatinine and that dosage reduction of
redniso1one may be attempted in patients with chronic renal
[uuilure undergoing hemodialysis.
However, pharmacokinetic studies determine mechanisms of
Jrug disposition, and only when drug effects are measured,
which are very complex for glucocorticoids, can clinical infer-
nces safely be drawn.
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